By Ben Butkus

Life Technologies this week reported that revenues from its Molecular Biology Systems division slid 2 percent in both the fourth quarter and full-year 2011, excluding foreign currency impact, amid company-wide revenue growth of 8 percent and 5 percent for Q4 and FY2011, respectively.

The lackluster MBS division revenues were due primarily to an expected decrease in qPCR royalties and continuing difficulties in government and academic markets, company executives said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.